內地次批國家帶量採購藥品掛網 業界指糖尿病、高血壓等多種常用藥價格大幅下降
上海市醫藥集中招標採購事務管理所正式發布《關於開展第二批全國藥品集中採購上海地區中選藥品掛網工作的通知》,第二批國家組織藥品集中採購中選藥品將正式在上海掛網。各企業需於2020年3月10日前,按要求規範填寫並上報所有上海地區中選供應藥品信息,執行時間另行通知。同日,雲南省藥品集中採購中心發布《關於第二批國家組織藥品集中採購中選藥品掛網交易有關事宜的通知》。掛網交易藥品為第二批國家組織藥品集中採購雲南中選及供貨清單藥品。同時,目錄對應的同廠、同品規老中標藥品,將在目錄內藥品掛網交易後停止掛網交易資格。有業內人士表示,隨著各地加速新一輪採購中選藥品的掛網,相關藥品將於近期正式執行第二批國家組織藥品集中採購中選藥品中選價,包括糖尿病、高血壓、癌症等相關藥物價格將大幅下調。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.